Cisterna Biologics, Inc.
Oceanside, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3349 Las Vegas Dr, Oceanside, CA 92054, USA
- Website
- cisternabx.com
- Founded
- 2022
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Trilink Biotechnologies, LLC | San Diego, CA | 325998 All Other Miscellaneous Chemical Product and Preparation Manufacturing |
| Modernatx, Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Dotquant LLC | Shoreline, WA | — |
| Lucerna Inc. | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Avery Bio Corporation | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Cisterna Biologics, Inc. is a biotechnology company based in Oceanside, California, registered as a minority-owned, self-certified small disadvantaged business. The company specializes in developing innovative mRNA production technologies, focusing on creating high-quality, purified mRNA with reduced contaminants for potential therapeutic applications. As a for-profit organization, Cisterna Biologics has positioned itself at the forefront of advanced mRNA synthesis techniques, targeting improvements in mRNA purity, production efficiency, and overall therapeutic potential.
The company has secured three significant federal grant awards from prominent scientific agencies, demonstrating its commitment to advancing mRNA technology. The National Center for Advancing Translational Sciences (NCATS) awarded a $349,746 grant to develop a platform for synthesizing high-quality, purified mRNA with minimal contaminants. The National Institute of General Medical Sciences (NIGMS) provided a $350,000 grant to develop cold-adapted RNA polymerases and a proprietary purification technology in collaboration with the University of Texas-Austin. Additionally, the National Science Foundation (NSF) awarded a $274,980 SBIR Phase I grant to create a cost-efficient mRNA production platform using yeast cells, with the goal of reducing manufacturing costs by up to 90% compared to current in vitro transcription methods. These grants collectively focus on innovative approaches to mRNA production, emphasizing improved purity, reduced immune response, enhanced therapeutic efficacy, and significantly lower production costs.
Quick answers
Is Cisterna Biologics, Inc. registered in SAM.gov?
Yes. Cisterna Biologics, Inc.'s SAM.gov registration is active through February 16, 2027.
What is Cisterna Biologics, Inc.'s CAGE code?
Cisterna Biologics, Inc.'s CAGE code is 9V2T6, and its Unique Entity ID (UEI) is VGCCUDX8F5P5.
What is Cisterna Biologics, Inc.'s most recent federal award?
Cisterna Biologics, Inc.'s most recent federal grant award is A novel approach to eliminate length impurities for high-quality mrna production (R43TR005424), from National Center for Advancing Translational Sciences (NIH), on August 1, 2025.
On GovTribe
See Cisterna Biologics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors